Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96


Hereditary breast cancer in the Han Chinese population.

Cao W, Wang X, Li JC.

J Epidemiol. 2013;23(2):75-84. Epub 2013 Jan 12. Review.


Identification of BRCA1/2 founder mutations in Southern Chinese breast cancer patients using gene sequencing and high resolution DNA melting analysis.

Kwong A, Ng EK, Wong CL, Law FB, Au T, Wong HN, Kurian AW, West DW, Ford JM, Ma ES.

PLoS One. 2012;7(9):e43994. doi: 10.1371/journal.pone.0043994. Epub 2012 Sep 7.


Identification of a comprehensive spectrum of genetic factors for hereditary breast cancer in a Chinese population by next-generation sequencing.

Yang X, Wu J, Lu J, Liu G, Di G, Chen C, Hou Y, Sun M, Yang W, Xu X, Zhao Y, Hu X, Li D, Cao Z, Zhou X, Huang X, Liu Z, Chen H, Gu Y, Chi Y, Yan X, Han Q, Shen Z, Shao Z, Hu Z.

PLoS One. 2015 Apr 30;10(4):e0125571. doi: 10.1371/journal.pone.0125571. eCollection 2015.


Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India.

Hedau S, Jain N, Husain SA, Mandal AK, Ray G, Shahid M, Kant R, Gupta V, Shukla NK, Deo SS, Das BC.

Breast Cancer Res Treat. 2004 Nov;88(2):177-86.


Prevalence and characterization of BRCA1 and BRCA2 germline mutations in Chinese women with familial breast cancer.

Zhang J, Pei R, Pang Z, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Xie Y.

Breast Cancer Res Treat. 2012 Apr;132(2):421-8. doi: 10.1007/s10549-011-1596-x. Epub 2011 May 26.


Prevalence of BRCA1 and BRCA2 mutations in non-familial breast cancer patients with high risks in Korea: the Korean Hereditary Breast Cancer (KOHBRA) Study.

Son BH, Ahn SH, Kim SW, Kang E, Park SK, Lee MH, Noh WC, Kim LS, Jung Y, Kim KS, Noh DY, Moon BI, Suh YJ, Lee JE, Choi DH, Kim SY, Jung SH, Yom CK, Lee H, Yang JH; KOHBRA Research Group and Korean Breast Cancer Society.

Breast Cancer Res Treat. 2012 Jun;133(3):1143-52. doi: 10.1007/s10549-012-2001-0. Epub 2012 Mar 2.


Evaluation of the need for routine clinical testing of PALB2 c.1592delT mutation in BRCA negative Northern Finnish breast cancer families.

Haanpää M, Pylkäs K, Moilanen JS, Winqvist R.

BMC Med Genet. 2013 Aug 13;14:82. doi: 10.1186/1471-2350-14-82.


The prevalence of PALB2 germline mutations in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives.

Cao AY, Huang J, Hu Z, Li WF, Ma ZL, Tang LL, Zhang B, Su FX, Zhou J, Di GH, Shen KW, Wu J, Lu JS, Luo JM, Yuan WT, Shen ZZ, Huang W, Shao ZM.

Breast Cancer Res Treat. 2009 Apr;114(3):457-62. doi: 10.1007/s10549-008-0036-z. Epub 2008 Apr 30.


Recurrent BRCA1 and BRCA2 germline mutations in ovarian cancer: a founder mutation of BRCA1 identified in the Chinese population.

Khoo US, Chan KY, Cheung AN, Xue WC, Shen DH, Fung KY, Ngan HY, Choy KW, Pang CP, Poon CS, Poon AY, Ozcelik H.

Hum Mutat. 2002 Mar;19(3):307-8.


The Fanconi anaemia/BRCA pathway and cancer susceptibility. Searching for new therapeutic targets.

García MJ, Benítez J.

Clin Transl Oncol. 2008 Feb;10(2):78-84. Review.


Interaction between BRCA1/BRCA2 and ATM/ATR associate with breast cancer susceptibility in a Chinese Han population.

Wang K, Ye Y, Xu Z, Zhang X, Hou Z, Cui Y, Song Y.

Cancer Genet Cytogenet. 2010 Jul 1;200(1):40-6. doi: 10.1016/j.cancergencyto.2010.03.006.


Novel mutations in the BRCA1 and BRCA2 genes in Iranian women with early-onset breast cancer.

Yassaee VR, Zeinali S, Harirchi I, Jarvandi S, Mohagheghi MA, Hornby DP, Dalton A.

Breast Cancer Res. 2002;4(4):R6. Epub 2002 Apr 16.


The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain.

Milne RL, Osorio A, Cajal TR, Vega A, Llort G, de la Hoya M, Díez O, Alonso MC, Lazaro C, Blanco I, Sánchez-de-Abajo A, Caldés T, Blanco A, Graña B, Durán M, Velasco E, Chirivella I, Cardeñosa EE, Tejada MI, Beristain E, Miramar MD, Calvo MT, Martínez E, Guillén C, Salazar R, San Román C, Antoniou AC, Urioste M, Benítez J.

Clin Cancer Res. 2008 May 1;14(9):2861-9. doi: 10.1158/1078-0432.CCR-07-4436.


Mutation analysis of BRIP1/BACH1 in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives.

Cao AY, Huang J, Hu Z, Li WF, Ma ZL, Tang LL, Zhang B, Su FX, Zhou J, Di GH, Shen KW, Wu J, Lu JS, Luo JM, Yuan WT, Shen ZZ, Huang W, Shao ZM.

Breast Cancer Res Treat. 2009 May;115(1):51-5. doi: 10.1007/s10549-008-0052-z. Epub 2008 May 16.


Breast cancer susceptibility: current knowledge and implications for genetic counselling.

Ripperger T, Gadzicki D, Meindl A, Schlegelberger B.

Eur J Hum Genet. 2009 Jun;17(6):722-31. doi: 10.1038/ejhg.2008.212. Epub 2008 Dec 17. Review.


The prevalence of BRCA1 and BRCA2 germline mutations in high-risk breast cancer patients of Chinese Han nationality: two recurrent mutations were identified.

Li WF, Hu Z, Rao NY, Song CG, Zhang B, Cao MZ, Su FX, Wang YS, He PQ, Di GH, Shen KW, Wu J, Lu JS, Luo JM, Liu XY, Zhou J, Wang L, Zhao L, Liu YB, Yuan WT, Yang L, Shen ZZ, Huang W, Shao ZM.

Breast Cancer Res Treat. 2008 Jul;110(1):99-109. Epub 2007 Sep 13.


[The clinical importance of a genetic analysis of moderate-risk cancer susceptibility genes in breast and other cancer patients from the Czech Republic].

Pohlreich P, Kleibl Z, Kleiblová P, Janatová M, Soukupová J, Macháčková E, Házová J, Vašíčková P, Sťahlová Hrabincová E, Navrátilová M, Svoboda M, Foretová L.

Klin Onkol. 2012;25 Suppl:S59-66. Review. Czech.


Methylation profiles of the BRCA1 promoter in hereditary and sporadic breast cancer among Han Chinese.

Pang D, Zhao Y, Xue W, Shan M, Chen Y, Zhang Y, Zhang G, Liu F, Li D, Yang Y.

Med Oncol. 2012 Sep;29(3):1561-8. doi: 10.1007/s12032-011-0100-0. Epub 2011 Nov 11.


[BRCA1/2 gene mutation in Chinese familial breast cancer patients: a multi-center report of 115 cases].

Hu Z, Li WF, Liu XY, Zhang B, Cao MZ, Wang YS, Zhao L, Song CG, Lu JS, Wu J, DI GH, Shen KW, Han QX, Shen ZZ, Huang W, Shao ZM.

Zhonghua Yi Xue Za Zhi. 2008 Sep 9;88(34):2383-6. Chinese.

Items per page

Supplemental Content

Write to the Help Desk